Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy

Farmer, Hannah, McCabe, Nuala, Lord, Christopher J., Tutt, Andrew N. J., Johnson, Damian A., Richardson, Tobias B., Santarosa, Manuela, Dillon, Krystyna J. +6 more·2005·Nature
DOI 10.1038/nature03445

Cited by (1,041)

Items 101–200 of 1,041

  1. Genetics and biology of prostate cancer
    Guocan Wang, Di Zhao, Denise J. Spring, Ronald Anthony DePinho · 2018 · Genes & Development
  2. Platinum Resistance: The Role of DNA Repair Pathways
    Lainie P. Martin, Thomas C. Hamilton, Russell J. Schilder · 2008 · Clinical Cancer Research
  3. A decade of clinical development of PARP inhibitors in perspective
    Mateo, J., Lord, C.J., Serra, V., Tutt, A., Balmaña, J., Castroviejo-Bermejo, M., Cruz, C., Oaknin, A., Kaye, S.B., de Bono, J.S. · 2019 · Annals of Oncology
  4. Laying a trap to kill cancer cells: PARP inhibitors and their mechanisms of action
    Yves G. Pommier, Mark J. O’Connor, Johann Sebastian De Bono · 2016 · Science Translational Medicine
  5. Biological Consequences of Radiation-induced DNA Damage: Relevance to Radiotherapy
    Martine E. Lomax, Lisa K. Folkes, Peter O'Neill · 2013 · Clinical Oncology
  6. PARP Inhibitors: Clinical Relevance, Mechanisms of Action and Tumor Resistance
    Maddison Rose, Joshua T. Burgess, Kenneth John O'Byrne, Derek J. Richard, Emma Bolderson · 2020 · Frontiers in Cell and Developmental Biology
  7. On PAR with PARP: cellular stress signaling through poly(ADP-ribose) and PARP-1
    Xin Luo, W. Lee Kraus · 2012 · Genes & Development
  8. The nuclear deubiquitinase BAP1 is commonly inactivated by somatic mutations and 3p21.1 losses in malignant pleural mesothelioma
    Bott, Matthew, Brevet, Marie, Taylor, Barry S, Shimizu, Shigeki, Ito, Tatsuo, Wang, Lu, Creaney, Jenette, Lake, Richard A, Zakowski, Maureen F, Reva, Boris et al. · 2011 · Nature Genetics
  9. Triple-negative breast cancer—current status and future directions
    Oleg Gluz, C Liedtke, Nina Gottschalk, Lajos Pusztai, Ulrike Anneliese Nitz, Nadia Harbeck · 2009 · Annals of Oncology
  10. PARPs and ADP-ribosylation: recent advances linking molecular functions to biological outcomes
    Gupte, Rebecca, Liu, Ziying, Kraus, W. Lee · 2017 · Genes & Development
  11. Rad51-mediated replication fork reversal is a global response to genotoxic treatments in human cells
    Ralph Zellweger, Damian Dalcher, Karun Mutreja, Matteo Berti, Jonas Andreas Schmid, Raquel Herrador, Alessandro Vindigni, Massimo Lopes · 2015 · The Journal of Cell Biology
  12. PARP and PARG inhibitors in cancer treatment
    Dea Slade · 2020 · Genes & Development
  13. Synthetic lethality and cancer
    Nigel J. O’Neil, Melanie L. Bailey, Philip Hieter · 2017 · Nature Reviews Genetics
  14. Mechanisms and insights into drug resistance in cancer
    Hiba Ahmad Zahreddine, Katherine L. B. Borden · 2013 · Frontiers in Pharmacology
  15. MutationalPatterns: comprehensive genome-wide analysis of mutational processes
    Blokzijl, Francis, Janssen, Roel, van Boxtel, Ruben, Cuppen, Edwin · 2018 · Genome Medicine
  16. DNA Damage and Repair Biomarkers of Immunotherapy Response
    Kent William Mouw, Michael S. Goldberg, Panagiotis A. Konstantinopoulos, Alan D. D’Andrea · 2017 · Cancer Discovery
  17. Evolution of the cancer genome
    Lucy R. Yates, Peter J. Campbell · 2012 · Nature Reviews Genetics
  18. Homologous recombination and its regulation
    Lumír Krejčí, Veronika Altmannová, M. Spirek, Xiaolan Zhao · 2012 · Nucleic Acids Research
  19. ATM and ATR as therapeutic targets in cancer
    Anika M. Weber, Anderson Joseph Ryan · 2014 · Pharmacology & Therapeutics
  20. DNA double-strand break repair: From mechanistic understanding to cancer treatment
    HELLEDAY, T, LO, J, VANGENT, D, ENGELWARD, B · 2007 · DNA Repair
  21. Synthetic lethal targeting of PTEN mutant cells with PARP inhibitors
    Ana M. Mendes‐Pereira, Sarah A. Martin, Rachel Brough, Afshan McCarthy, J R Taylor, Jung‐Sik Kim, Todd A. Waldman, Christopher J. Lord, Alan Ashworth · 2009 · EMBO Molecular Medicine
  22. Microhomology-Mediated End Joining: A Back-up Survival Mechanism or Dedicated Pathway?
    Sfeir, Agnel, Symington, Lorraine S. · 2015 · Trends in Biochemical Sciences
  23. Olaparib in patients with metastatic castration-resistant prostate cancer with DNA repair gene aberrations (TOPARP-B): a multicentre, open-label, randomised, phase 2 trial
    Joaquı́n Mateo, Núria Porta, Diletta Bianchini, Ursula McGovern, Tony Elliott, Robert J. Jones, Isabel Syndikus, Christy Ralph, Suneil Jain, Mohini Anna Varughese et al. · 2019 · The Lancet Oncology
  24. Gene Essentiality Profiling Reveals Gene Networks and Synthetic Lethal Interactions with Oncogenic Ras
    Wang, Tim, Yu, Haiyan, Hughes, Nicholas W., Liu, Bingxu, Kendirli, Arek, Klein, Klara, Chen, Walter W., Lander, Eric S., Sabatini, David M. · 2017 · Cell
  25. The emerging clinical relevance of genomics in cancer medicine
    Michael F. Berger, Elaine R. Mardis · 2018 · Nature Reviews Clinical Oncology
  26. Realizing the promise of cancer predisposition genes
    Nazneen Rahman · 2014 · Nature
  27. The roles of BRCA1 and BRCA2 and associated proteins in the maintenance of genomic stability
    Katrin Kemp Gudmundsdottir, Alan Ashworth · 2006 · Oncogene
  28. Biology, Metastatic Patterns, and Treatment of Patients with Triple-Negative Breast Cancer
    Carey K. Anders, LA Carey · 2009 · Clinical Breast Cancer
  29. Targeting DNA Repair in Cancer: Beyond PARP Inhibitors
    Jessica S. Brown, Brent O’Carrigan, Stephen P. Jackson, Timothy Anthony Yap · 2016 · Cancer Discovery
  30. The effects of deregulated DNA damage signalling on cancer chemotherapy response and resistance
    Bouwman, Peter, Jonkers, Jos · 2012 · Nature Reviews Cancer
  31. Parthanatos: mitochondrial‐linked mechanisms and therapeutic opportunities
    Fatokun, Amos A, Dawson, Valina L, Dawson, Ted M · 2014 · British Journal of Pharmacology
  32. Regulation of DNA Damage Responses by Ubiquitin and SUMO
    Jackson, Stephen P., Durocher, Daniel · 2013 · Molecular Cell
  33. Review of Poly (ADP-ribose) Polymerase (PARP) Mechanisms of Action and Rationale for Targeting in Cancer and Other Diseases
    Julio C. Morales, Long-Shan Li, Farjana Jahan Fattah, Ying Dong, Erik A. Bey, Malina Patel, Jinming Gao, David A. Boothman · 2013 · Critical Reviews in Eukaryotic Gene Expression
  34. PARP1-dependent Kinetics of Recruitment of MRE11 and NBS1 Proteins to Multiple DNA Damage Sites
    Jean-François Haince, Darin McDonald, Amélie Rodrigue, Ugo Déry, Jean‐Yves Masson, Michael J. Hendzel, Guy G. Poirier · 2007 · Journal of Biological Chemistry
  35. RIF1 Is Essential for 53BP1-Dependent Nonhomologous End Joining and Suppression of DNA Double-Strand Break Resection
    J. Ross Chapman, Patricia Barral, Jean‐Baptiste Vannier, Valérie Borel, Martin Steger, Antonia Tomás‐Loba, Alessandro A. Sartori, Ian R. Adams, Facundo D. Batista, Simon J. Boulton · 2013 · Molecular Cell
  36. PI3K Inhibition Impairs BRCA1/2 Expression and Sensitizes BRCA-Proficient Triple-Negative Breast Cancer to PARP Inhibition
    Yasir H. Ibrahim, Celina García-García, Violeta Serra, Lei He, Kristine Torres‐Lockhart, Aleix Prat, Pilar Antón, Patricia Cozar, Marta Guzmán, Judit Grueso et al. · 2012 · Cancer Discovery
  37. Clinical and pathologic characteristics of patients with BRCA-positive and BRCA-negative breast cancer.
    Deann P. D. Atchley, C. Albarracin, Adriana López, V. Valero, Chris Amos, A. González-Angulo, G. Hortobagyi, B. Arun · 2008 · Journal of Clinical Oncology
  38. 4-[3-(4-Cyclopropanecarbonylpiperazine-1-carbonyl)-4-fluorobenzyl]-2H-phthalazin-1-one: A Novel Bioavailable Inhibitor of Poly(ADP-ribose) Polymerase-1
    Keith A. Menear, Claire Adcock, Robert Boulter, Xiaoling F. Cockcroft, Louise Copsey, Aaron N. Cranston, Krystyna J. Dillon, Jan Drzewiecki, Sheila Garman, Sylvie Gomez et al. · 2008 · Journal of Medicinal Chemistry
  39. PARP is activated at stalled forks to mediate Mre11‐dependent replication restart and recombination
    Helen E. Bryant, Eva Petermann, Niklas Schultz, Ann‐Sofie Jemth, Olga Loseva, Natalia Issaeva, Fredrik Johansson, Serena Fernandez, Peter McGlynn, Thomas Helleday · 2009 · The EMBO Journal
  40. Prostate Cancer, Version 4.2023, NCCN Clinical Practice Guidelines in Oncology
    Edward M. Schaeffer, Sandy Srinivas, Nabil Adra, Yi An, Daniel Ari Barocas, Rhonda Lynn Bitting, Alan Haruo Bryce, Brian Francis Chapin, Heather H. Cheng, Anthony Victor D'Amico et al. · 2023 · Journal of the National Comprehensive Cancer Network
  41. Ionizing Radiation-Induced DNA Damage, Response, and Repair
    Wil L. Santivasi, Fen Xia · 2013 · Antioxidants and Redox Signaling
  42. Ovarian carcinomas: five distinct diseases with different origins, genetic alterations, and clinicopathological features
    Jaime Prat · 2012 · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin
  43. Transformation of the Fallopian Tube Secretory Epithelium Leads to High-Grade Serous Ovarian Cancer in Brca;Tp53;Pten Models
    Perets, Ruth, Wyant, Gregory A., Muto, Katherine W., Bijron, Jonathan G., Poole, Barish B., Chin, Kenneth T., Chen, Jin Yun H., Ohman, Anders W., Stepule, Corey D., Kwak, Soongu et al. · 2013 · Cancer Cell
  44. PARPi Triggers the STING-Dependent Immune Response and Enhances the Therapeutic Efficacy of Immune Checkpoint Blockade Independent of BRCAness
    Jianfeng Shen, Wei Zhao, Zhenlin Ju, Lulu Wang, Yang Peng, Marilyne Labrie, Timothy Anthony Yap, Gordon Brent Mills, Guang Peng · 2018 · Cancer Research
  45. REV7 counteracts DNA double-strand break resection and affects PARP inhibition
    Guotai Xu, J. Ross Chapman, Inger Brandsma, Jingsong Yuan, Martin Mistrík, Peter Bouwman, Jiřina Bártková, Ewa Gogola, Daniël O. Warmerdam, Marco Barazas et al. · 2015 · Nature
  46. How the Fanconi Anemia Pathway Guards the Genome
    George‐Lucian Moldovan, Alan D. D’Andrea · 2009 · Annual Review of Genetics
  47. The diverse biological roles of mammalian PARPS, a small but powerful family of poly-ADP-ribose polymerases
    Paul, O. Hassa · 2007 · Frontiers in bioscience
  48. Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: a randomised phase 2 study
    Joyce F. Liu, William Thomas Barry, Michael J. Birrer, Jung-Min Lee, Ronald J. Buckanovich, Gini F. Fleming, B.J. Rimel, Mary Kathleen Buss, Sreenivasa R. Nattam, Jean A. Hurteau et al. · 2014 · The Lancet Oncology
  49. BRCA1: cell cycle checkpoint, genetic instability, DNA damage response and cancer evolution
    Chu‐Xia Deng · 2006 · Nucleic Acids Research
  50. The role of double-strand break repair — insights from human genetics
    Mark O’Driscoll, Penny Ann Jeggo · 2005 · Nature Reviews Genetics
  51. High-content CRISPR screening
    Christoph Bock, Paul Datlinger, Florence M. Chardon, Matthew A. Coelho, Matthew B. Dong, Keith A. Lawson, Tian Lu, Laetitia Maroc, Thomas M. Norman, Bicna Song et al. · 2022 · Nature Reviews Methods Primers
  52. BRCA1 dysfunction in sporadic basal-like breast cancer
    Nicholas C. Turner, J. S. Reis-Filho, A M Russell, Robert J. Springall, K Ryder, David Steele, Kay Savage, C E Gillett, Fernando Carlos Schmitt, Alan Ashworth et al. · 2006 · Oncogene
  53. Incidence and Outcome of BRCA Mutations in Unselected Patients with Triple Receptor-Negative Breast Cancer
    Ana Maria Gonzalez-Angulo, Kirsten M. Timms, Shuying Liu, Huiqin Chen, Jennifer Keating Litton, Jennifer Potter, Jerry S. S. Lanchbury, Katherine Stemke‐Hale, Bryan T. Hennessy, Banu Arun et al. · 2011 · Clinical Cancer Research
  54. Poly(ADP-ribose) polymerase inhibition: past, present and future
    Nicola J. Curtin, Csaba Szabó · 2020 · Nature Reviews Drug Discovery
  55. PARP inhibition elicits STING-dependent antitumor immunity in brca1-deficient ovarian cancer
    Ding, Liya, Kim, Hye-Jung, Wang, Qiwei, Kearns, Michael, Jiang, Tao, Ohlson, Carolynn E., Li, Ben B., Xie, Shaozhen, Liu, Joyce F., Stover, Elizabeth H. et al. · 2018 · Cell Reports
  56. Histological types of breast cancer: How special are they?
    Britta Weigelt, Felipe Correa Geyer, Jorge Sergio Reis-Filho · 2010 · Molecular Oncology
  57. Enabling personalized cancer medicine through analysis of gene-expression patterns
    Laura van ‘t Veer, René Bernards · 2008 · Nature
  58. PARP inhibitor resistance: the underlying mechanisms and clinical implications
    He Li, Zhaoyi Liu, Nayiyuan Wu, Yongchang Chen, Quan Cheng, Jing Wang · 2020 · Molecular Cancer
  59. Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial
    Amit M. Oza, David Cibula, Ana Oaknin Benzaquen, Christopher John Poole, Ron H.J. Mathijssen, Gabe S. Sonke, Nicoletta Colombo, Jiří Špaček, Peter Vuylsteke, Holger W. Hirte et al. · 2014 · The Lancet Oncology
  60. The DNA Damage Response: Implications for Tumor Responses to Radiation and Chemotherapy
    Goldstein, Michael, Kastan, Michael B. · 2015 · Annual Review of Medicine
  61. Nonhomologous end joining drives poly(ADP-ribose) polymerase (PARP) inhibitor lethality in homologous recombination-deficient cells
    Anand G. Patel, Jann Nagina Sarkaria, Scott H. Kaufmann · 2011 · Proceedings of the National Academy of Sciences
  62. Current approaches in treatment of triple-negative breast cancer.
    Hanan Ahmed Wahba, Hend Ahmed El-Hadaad · 2015 · Europe PMC (PubMed Central)
  63. Talazoparib plus enzalutamide in men with first-line metastatic castration-resistant prostate cancer (TALAPRO-2): a randomised, placebo-controlled, phase 3 trial
    Agarwal, Neeraj, Azad, Arun A, Carles, Joan, Fay, Andre P, Matsubara, Nobuaki, Heinrich, Daniel, Szczylik, Cezary, De Giorgi, Ugo, Young Joung, Jae, Fong, Peter C C et al. · 2023 · The Lancet
  64. Niraparib monotherapy for late-line treatment of ovarian cancer (QUADRA): a multicentre, open-label, single-arm, phase 2 trial
    Kathleen N. Moore, Angeles Alvarez Secord, Melissa Ann Geller, David Scott Miller, Noelle Gillette Cloven, Gini F. Fleming, Andrea E. Wahner Hendrickson, Masoud Azodi, Paul DiSilvestro, Amit M. Oza et al. · 2019 · The Lancet Oncology
  65. Germline mutations in RAD51D confer susceptibility to ovarian cancer
    Chey Loveday, Clare Turnbull, Emma Ramsay, Deborah Hughes, Elise Ruark, Jessica R. Frankum, Georgina R. Bowden, Bolot Kalmyrzaev, Margaret Warren-Perry, Katie M.G. Snape et al. · 2011 · Nature Genetics
  66. Triple‑negative breast cancer therapy: Current and future perspectives (Review)
    Kwang‐Ai Won, Charles Spruck · 2020 · International Journal of Oncology
  67. NCCN Guidelines Insights: Prostate Cancer, Version 1.2021
    Edward Matthew Schaeffer, Sandy Srinivas, Emmanuel S. Antonarakis, Andrew J. Armstrong, Justin E. Bekelman, Heather H. Cheng, Anthony Victor D'Amico, Brian J. Davis, Neil Bipinchandra Desai, Tanya Barauskas Dorff et al. · 2021 · Journal of the National Comprehensive Cancer Network
  68. Understanding and overcoming resistance to PARP inhibitors in cancer therapy
    Mariana Paes Dias, Sarah C. Moser, Shridar Ganesan, Jos Jonkers · 2021 · Nature Reviews Clinical Oncology
  69. ARID1A Deficiency Impairs the DNA Damage Checkpoint and Sensitizes Cells to PARP Inhibitors
    Shen, Jianfeng, Peng, Yang, Wei, Leizhen, Zhang, Wei, Yang, Lin, Lan, Li, Kapoor, Prabodh, Ju, Zhenlin, Mo, Qianxing, Shih, Ie-Ming et al. · 2015 · Cancer Discovery
  70. Acetylation limits 53BP1 association with damaged chromatin to promote homologous recombination
    Tang, Jiangbo, Cho, Nam Woo, Cui, Gaofeng, Manion, Erica M, Shanbhag, Niraj M, Botuyan, Maria Victoria, Mer, Georges, Greenberg, Roger A · 2013 · Nature Structural & Molecular Biology
  71. DNA damage signalling guards against activated oncogenes and tumour progression
    Bartek, J, Bartkova, J, Lukas, J · 2007 · Oncogene
  72. MTH1 inhibition eradicates cancer by preventing sanitation of the dNTP pool
    Helge Gad, Tobias Koolmeister, Ann‐Sofie Jemth, Saeed Eshtad, Sylvain A. Jacques, Cecilia E. Ström, Linda M. Svensson, Niklas Schultz, Thomas Lundbäck, Berglind Osk Einarsdottir et al. · 2014 · Nature
  73. Loss of 53BP1 Causes PARP Inhibitor Resistance in Brca1 -Mutated Mouse Mammary Tumors
    Janneke E. Jaspers, Ariena J. Kersbergen, Ute Boon, Wendy Sol, Liesbeth van Deemter, Serge A.L. Zander, Rinske Drost, Ellen Wientjens, Jiuping Jay Ji, Amal Aly et al. · 2012 · Cancer Discovery
  74. High speed of fork progression induces DNA replication stress and genomic instability
    Maya-Mendoza, Apolinar, Moudry, Pavel, Merchut-Maya, Joanna Maria, Lee, MyungHee, Strauss, Robert, Bartek, Jiri · 2018 · Nature
  75. Chemotherapeutic Approaches for Targeting Cell Death Pathways
    Marco Ricci, Wei‐Xing Zong · 2006 · The Oncologist
  76. Alternative lengthening of telomeres renders cancer cells hypersensitive to ATR inhibitors
    Rachel Litman Flynn, Kelli E. Cox, Maya Jeitany, Hiroaki Wakimoto, Alysia R. Bryll, Neil J. Ganem, Francesca Bersani, José Ramón Pineda, Mario L. Suvà, Cyril H. Benes et al. · 2015 · Science
  77. Rational combinations of targeted cancer therapies: background, advances and challenges
    Jin, Haojie, Wang, Liqin, Bernards, René · 2023 · Nature Reviews Drug Discovery
  78. Ubiquitin ligases in oncogenic transformation and cancer therapy
    Daniela Senft, Jianfei Qi, Ze’ev A. Ronai · 2017 · Nature reviews. Cancer
  79. Identification and use of biomarkers in treatment strategies for triple‐negative breast cancer subtypes
    Brian David Lehmann, Jennifer A. Pietenpol · 2013 · The Journal of Pathology
  80. Beyond chemotherapy: targeted therapies in ovarian cancer
    Timothy A. Yap, Craig P. Carden, Stan B. Kaye · 2009 · Nature reviews. Cancer
  81. Unravelling the biology of SCLC: implications for therapy
    Joshua K. Sabari, Benjamin H. Lok, James H. Laird, John Thomas Poirier, Charles M. Rudin · 2017 · Nature Reviews Clinical Oncology
  82. The diverse roles and clinical relevance of PARPs in DNA damage repair: Current state of the art
    Mike De Vos, Valérie Schreiber, Françoise Dantzer · 2012 · Biochemical Pharmacology
  83. Therapeutic targeting of the hypoxic tumour microenvironment
    Dean C. Singleton, Andrew Macann, William Robert Wilson · 2021 · Nature Reviews Clinical Oncology
  84. Mechanisms of PARP inhibitor sensitivity and resistance
    Alan D. D’Andrea · 2018 · DNA repair
  85. Breast Cancer Treatments: Updates and New Challenges
    Anna Burguin, Caroline Diorio, Francine Durocher · 2021 · Journal of Personalized Medicine
  86. <i>ATM</i> Mutations in Patients with Hereditary Pancreatic Cancer
    Roberts, Nicholas J., Jiao, Yuchen, Yu, Jun, Kopelovich, Levy, Petersen, Gloria M., Bondy, Melissa L., Gallinger, Steven, Schwartz, Ann G., Syngal, Sapna, Cote, Michele L. et al. · 2012 · Cancer Discovery
  87. Latest research and treatment of advanced-stage epithelial ovarian cancer
    Robert Louis Coleman, Bradley J. Monk, Anil K. Sood, Thomas J. Herzog · 2013 · Nature Reviews Clinical Oncology
  88. The emerging landscape of breast cancer susceptibility
    Stratton, Michael R, Rahman, Nazneen · 2008 · Nature Genetics
  89. Detection of inherited mutations for breast and ovarian cancer using genomic capture and massively parallel sequencing
    Tom Walsh, Ming K. Lee, Silvia Casadei, Anne Thornton, Sunday M. Stray, Christopher C. Pennil, Alex S. Nord, Jessica B. Mandell, Elizabeth M. Swisher, Mary‐Claire King · 2010 · Proceedings of the National Academy of Sciences
  90. ESMO recommendations on predictive biomarker testing for homologous recombination deficiency and PARP inhibitor benefit in ovarian cancer
    Rowan E. Miller, Alexandra F. Leary, Clare L. Scott, Violeta Serra, Christopher J. Lord, David D.L. Bowtell, David Kuang-Fu Chang, Dale W. Garsed, Jos Jonkers, Jonathan Andrew Ledermann et al. · 2020 · Annals of Oncology
  91. Gene Expression Profile of BRCAness That Correlates With Responsiveness to Chemotherapy and With Outcome in Patients With Epithelial Ovarian Cancer
    Panagiotis A. Konstantinopoulos, Dimitrios Spentzos, Beth Y. Karlan, Toshiyasu Taniguchi, Elena Fountzilas, Nancy J. Francoeur, Douglas A. Levine, Stephen A. Cannistra · 2010 · Journal of Clinical Oncology
  92. Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer
    Charles E. Geyer, Judy Ellen Garber, Richard D. Gelber, Greg Yothers, M. Taboada, L. Ross, Priya Rastogi, Karen Y. Cui, Amal Arahmani, Gursel Aktan et al. · 2022 · Annals of Oncology
  93. BMN 673, a Novel and Highly Potent PARP1/2 Inhibitor for the Treatment of Human Cancers with DNA Repair Deficiency
    Yuqiao Shen, Farah L. Rehman, Ying Feng, Julia Boshuizen, Ilirjana Bajrami, Richard J. R. Elliott, Bing Wang, Christopher J. Lord, Leonard E. Post, Alan Ashworth · 2013 · Clinical Cancer Research
  94. Synthetic lethality as an engine for cancer drug target discovery
    Alan Huang, Levi A. Garraway, Alan Ashworth, Barbara L. Weber · 2019 · Nature Reviews Drug Discovery
  95. Synthetic Lethality and Cancer Therapy: Lessons Learned from the Development of PARP Inhibitors
    Christopher J. Lord, Andrew N.J. Tutt, Alan Ashworth · 2014 · Annual Review of Medicine
  96. Somatic loss of BRCA1 and p53 in mice induces mammary tumors with features of human BRCA1 -mutated basal-like breast cancer
    Xiaoling Liu, Henne H. Holstege, Hanneke M.L. van der Gulden, Marcelle Treur-Mulder, John Zevenhoven, Arno Velds, Ron M Kerkhoven, Martin H. van Vliet, Lodewyk F.A. Wessels, Johannes L. Peterse et al. · 2007 · Proceedings of the National Academy of Sciences
  97. Phase II, Open-Label, Randomized, Multicenter Study Comparing the Efficacy and Safety of Olaparib, a Poly (ADP-Ribose) Polymerase Inhibitor, and Pegylated Liposomal Doxorubicin in Patients With BRCA1 or BRCA2 Mutations and Recurrent Ovarian Cancer
    Stan B. Kaye, Jan Lubiński, Ursula A. Matulonis, Joo Ern Ang, Charlie Gourley, Beth Y. Karlan, Amnon Amit, Katherine M. Bell‐McGuinn, Lee-may Chen, Michael Leonard Friedlander et al. · 2011 · Journal of Clinical Oncology
  98. DNA Repair Network Analysis Reveals Shieldin as a Key Regulator of NHEJ and PARP Inhibitor Sensitivity
    Rajat Gupta, Kumar Somyajit, Takeo Narita, Elina Maskey, Andre Stanlie, Magdalena Kremer, Dimitris Typas, Michael Lammers, Niels Mailand, André Nussenzweig et al. · 2018 · Cell
  99. "BRCAness" syndrome in ovarian cancer: a case-control study describing the clinical features and outcome of patients with epithelial ovarian cancer associated with BRCA1 and BRCA2 mutations.
    D. S. Tan, C. Rothermundt, K. Thomas, E. Bancroft, R. Eeles, S. Shanley, A. Ardern-jones, A. Norman, S. Kaye, M. Gore · 2008 · Journal of Clinical Oncology
  100. Newly diagnosed and relapsed epithelial ovarian cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
    Antonio González-Martı́n, Philipp Harter, Alexandra F. Leary, Domenica Lorusso, Rowan E. Miller, Bhavana Pothuri, I. Ray-Coquard, David S.P. Tan, E. Bellet, Ana Oaknin et al. · 2023 · Annals of Oncology